SAGE is currently trading at $24.93, up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at $147.98 up 1.21 percent or $1.78 on the Nasdaq. The views and opinions expressed herein ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ: SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

Sage Advisors LLC lifted its holdings in Apple Inc. (NASDAQ:AAPL – Free Report) by 4.0% during the third quarter, according ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...